Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Clinical characteristics and outcomes of extranodal marginal zone lymphoma of pulmonary mucosa-associated lymphoid tissue: A single-center retrospective study

Yu Qiu, Chunxia Zhang, Min Wang, Yayue Gao, Qianqian Ju, Chao Guo, Yuan Huang, Jingya Wang, Yang Li, Liu Zixian, Ming Gong, Zhenling Li

Blood (2025) 146 (Supplement 1): 7132.

https://doi.org/10.1182/blood-2025-7132

Published: 2025

Journal Articles

Upfront maintenance therapy improves the prognosis of patients with diffuse large B-cell lymphoma in the era of novel agents: A multicenter retrospective study

Liwei Lv, Liu Zixian, Yan-ying Wang, Jie Li, He-Bing Zhou, Li Hong Li, Zhenling Li, Liang Wang

Blood (2025) 146 (Supplement 1): 7227.

https://doi.org/10.1182/blood-2025-7227

Published: 2025

Journal Articles

Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

Blood (2025) 146 (Supplement 1): 5830.

https://doi.org/10.1182/blood-2025-5830

Published: 2025

Journal Articles

Does intensive consolidation confer a clinical advantage over continued less intensive therapy in elderly patients with Acute Myeloid Leukemia in first remission following azacitidine plus venetoclax induction?

Blood (2025) 146 (Supplement 1): 5162.

https://doi.org/10.1182/blood-2025-5162

Published: 2025

Journal Articles

Mitoxantrone hydrochloride liposome, gemcitabine, vinorelbine with or without anti-CD20 antibody (GVM±CD20) in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: A prospective, multicenter, Phase Ⅱ study

Blood (2025) 146 (Supplement 1): 1919.

https://doi.org/10.1182/blood-2025-1919

Published: 2025

Journal Articles

Interim results of a multi-center clinical trial evaluating copy number aberrations via shallow whole-genome sequencing (LeukoPrint) in Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 5245.

https://doi.org/10.1182/blood-2025-5245

Published: 2025

Journal Articles

Is autologous hematopoietic stem cell transplantation as consolidation therapy superior to chemotherapy alone in newly diagnosed intermediate-high risk DLBCL patients?

Shuozi Liu, Lan Ma, Hui Liu, Jiefei Bai, Wenrong Huang, JunLi Chen, Li Bao, Shan Gao, Wanling Sun, Zhenling Li, Min Wang, Hongmei Jing

Blood (2025) 146 (Supplement 1): 1888.

https://doi.org/10.1182/blood-2025-1888

Published: 2025

Journal Articles

Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Blood (2024) 144 (Supplement 1): 4417.

https://doi.org/10.1182/blood-2024-204513

Published: 2024

Journal Articles

Efficacy and Safety of a New Regime Containing PD1 Antibody and Pegaspargase for Advanced-Stage or Relapsed/Refractory Natural Killer/T Cell Lymphoma

Jie Chen, Linjun Zhao, Chongyang Wu, Haifeng Yu, Zhenling Li, Lihong Liu, Da Gao, Ying Sun, Xiaolei Wei, Yuanbin Wu, Yue Wang, Yuqin Song, Jun Zhu, Weiping Liu

Blood (2024) 144 (Supplement 1): 1686.

https://doi.org/10.1182/blood-2024-207412

Published: 2024

Journal Articles

EX103, a Newly Re-Designed CD20×CD3 Molecule, Induces High Response in Heavily Pretreated Relapsed/Refractory (R/R) Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL)

Mingyuan Sun, Lugui Qiu, Keshu Zhou, Kai Hu, Chunkang Chang, Dong Wu, Zhenling Li, Ming Gong, Wenjun Zhang, Daniel Yang, Jiali Lu, Junyuan Qi

Blood (2024) 144 (Supplement 1): 3103.

https://doi.org/10.1182/blood-2024-193606

Published: 2024

Journal Articles

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Shenmiao Yang, Huayuan Zhu, Ru Feng, Xutao Guo, Ting Niu, Jian-Qing Mi, Zhenling Li, Qianqian Ju, Liru Wang, Yujun Dong, Bingjie Wang, Liang Wang, Wanling Sun, Fang Fang, Liping Su, Yu Zhao, Xiaojun Huang, Jianyong Li

Blood (2024) 144 (Supplement 1): 6773.

https://doi.org/10.1182/blood-2024-206560

Published: 2024

Journal Articles

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: Preliminary Analysis from a Phase 2, Prospective, Multicenter Study

Blood (2024) 144 (Supplement 1): 1978.

https://doi.org/10.1182/blood-2024-201978

Published: 2024

Journal Articles

In-Class Transition (iCT) of Proteasome Inhibitor-Based Therapy Prolongs Progression-Free Survival in High-Risk Myeloma Patients: A Real-World Chinese Cohort Study

Rong Fu, Hong Yu, Aijun Liu, Rui Hou, Zunmin Zhu, Junling Zhuang, Li Bao, Zhenling Li, Lihong Liu, Luoming Hua, Yanping Ma, Da Gao, ARong Jin, Xiaohui Suo, Wei Yang, Yuansong Bai, Deqiang Zheng, Wenming Chen

Blood (2024) 144 (Supplement 1): 7846.

https://doi.org/10.1182/blood-2024-209471

Published: 2024

Journal Articles

Outcomes and Clinical Practice Among Patient with Chronic Lymphocytic Leukemia Treated with Ibrutinib in China: A Real-World Experience

Shenmiao Yang, Ru Feng, Xutao Guo, Zhenling Li, Qianqian Ju, Yujun Dong, Bingjie Wang, Yu Zhao, Liang Wang, Wanling Sun, Fang Fang, Liru Wang, Liping Su, Xiaojun Huang

Blood (2024) 144 (Supplement 1): 7819.

https://doi.org/10.1182/blood-2024-210572

Published: 2024

Journal Articles

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Blood (2023) 142 (Supplement 1): 4754.

https://doi.org/10.1182/blood-2023-180736

Published: 2023

Journal Articles

Whole-Genome Sequencing for Copy Number Abnormalities in Multiple Myeloma Supersedes Karyotype Analysis and Fluorescent in Situ Hybridization

Mao Mao, Jiali Li, Shaobing Gao, Zhenling Li, Yinyin Chang, Xiangxiang He, Yuexin Cheng, Manqian Li, Chunxiao Yao, Shiyong Li, Dandan Zhu, Shichun Tu, Xi Zhang, Li Gao

Blood (2023) 142 (Supplement 1): 7171.

https://doi.org/10.1182/blood-2023-179732

Published: 2023

Journal Articles

Update Results of a Phase II Trial of Venetoclax in Combination with Azacitidine and Chidamide in Relapsed/Refractory Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4274.

https://doi.org/10.1182/blood-2023-182832

Published: 2023

Journal Articles

Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Higher Risk Myelodysplastic Syndromes (MDS)

Blood (2023) 142 (Supplement 1): 320.

https://doi.org/10.1182/blood-2023-174420

Published: 2023

Journal Articles

Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Ixazomib, Pegylated Liposomal Adriamycin, and Dexamethasone(IDd) in Elderly Frail Newly Diagnosed Multiple Myeloma with GA Score ≥2: A Prospective Multicenter Study

Li Bao, Min-qiu Lu, Peng Liu, Yu-Tong Wang, Junling Zhuang, Mei Zhang, Zhongjun Xia, Zhenling Li, Ying Yang, Zhenyu Yan, Hongmei Jing, Wenming Chen, Hebing Zhou, Rong Fu, Yuping Gong, Wenrong Huang, Yongqing Zhang

Blood (2022) 140 (Supplement 1): 12564–12565.

https://doi.org/10.1182/blood-2022-168068

Published: 2022

Journal Articles

Oligosecretory Waldenström Macroglobulinemia Patients Exhibit Excellent Treatment Response and Outcomes

Blood (2022) 140 (Supplement 1): 9289–9291.

https://doi.org/10.1182/blood-2022-157311

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Clinical characteristics and outcomes of extranodal marginal zone lymphoma of pulmonary mucosa-associated lymphoid tissue: A single-center retrospective study

Upfront maintenance therapy improves the prognosis of patients with diffuse large B-cell lymphoma in the era of novel agents: A multicenter retrospective study

Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

Does intensive consolidation confer a clinical advantage over continued less intensive therapy in elderly patients with Acute Myeloid Leukemia in first remission following azacitidine plus venetoclax induction?

Mitoxantrone hydrochloride liposome, gemcitabine, vinorelbine with or without anti-CD20 antibody (GVM±CD20) in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: A prospective, multicenter, Phase Ⅱ study

Interim results of a multi-center clinical trial evaluating copy number aberrations via shallow whole-genome sequencing (LeukoPrint) in Acute Myeloid Leukemia

Is autologous hematopoietic stem cell transplantation as consolidation therapy superior to chemotherapy alone in newly diagnosed intermediate-high risk DLBCL patients?

Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Efficacy and Safety of a New Regime Containing PD1 Antibody and Pegaspargase for Advanced-Stage or Relapsed/Refractory Natural Killer/T Cell Lymphoma

EX103, a Newly Re-Designed CD20×CD3 Molecule, Induces High Response in Heavily Pretreated Relapsed/Refractory (R/R) Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL)

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: Preliminary Analysis from a Phase 2, Prospective, Multicenter Study

In-Class Transition (iCT) of Proteasome Inhibitor-Based Therapy Prolongs Progression-Free Survival in High-Risk Myeloma Patients: A Real-World Chinese Cohort Study

Outcomes and Clinical Practice Among Patient with Chronic Lymphocytic Leukemia Treated with Ibrutinib in China: A Real-World Experience

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Whole-Genome Sequencing for Copy Number Abnormalities in Multiple Myeloma Supersedes Karyotype Analysis and Fluorescent in Situ Hybridization

Update Results of a Phase II Trial of Venetoclax in Combination with Azacitidine and Chidamide in Relapsed/Refractory Acute Myeloid Leukemia

Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Higher Risk Myelodysplastic Syndromes (MDS)

Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Ixazomib, Pegylated Liposomal Adriamycin, and Dexamethasone(IDd) in Elderly Frail Newly Diagnosed Multiple Myeloma with GA Score ≥2: A Prospective Multicenter Study

Oligosecretory Waldenström Macroglobulinemia Patients Exhibit Excellent Treatment Response and Outcomes

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only